Please login to the form below

telaprevir

This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

Latest news

Access to new hep C treatments put under the spotlight

telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
FDA approves four new medicines across multiple areas

and Vertex' Incivek (telaprevir).
J&J starts to feel biosimilar competition bite

its toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Top biotech firms saw sales jump in 2014

Dion added: “ This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
The end of hepatitis C?

The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some ... Merck &Co. III. paritaprevir.

More from news
Approximately 2 fully matching, plus 47 partially matching documents found.

Latest Intelligence

Deal Watch table for November 2013

172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
Interview: Cesar Rodriguez, Janssen

Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager / Account Director: Great salary and bebefits

Editor – Medical Education Agency – Bucks: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Project Manager, Medical Communications, Oxford: Excellent Salary

Medical Writer, e-learning/ training, London: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Scientific Director: Great salary and bebefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Subscribe to our email news alerts

PMHub

Add my company

Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...